Importance of pan-RAF inhibitors in the future of melanoma treatment

Benefits and drawbacks of combinations of BRAF inhibitors and immunotherapyПодробнее

Dr. Flaherty Discusses BRAF Inhibitors in MelanomaПодробнее

The future of immunotherapy in melanomaПодробнее

Dr. Ribas on the Outlook for BRAF Inhibitors in MelanomaПодробнее

The current and future treatment of metastatic melanomaПодробнее

The Revolution in Molecular Therapy of MelanomaПодробнее

Dr. Liebman on Toxicities of BRAF Inhibitors in MelanomaПодробнее

Evaluating the role of pan-RAF inhibitors in RAF and RAS mutant tumorsПодробнее

Inhibition of MEK to Treat Cancer: Focus on MelanomaПодробнее

Dr. Glaucomflecken Explains: Nivolumab plus Ipilimumab in Advanced MelanomaПодробнее

What is the future of melanoma immunotherapyПодробнее

Mixed Media: Art and Science of Combination Therapy for Metastatic MelanomaПодробнее

Phase 2 studies of BRAF plus MEK inhibitors to treat melanomaПодробнее

Development of novel treatments in melanoma patients with BRAF mutationsПодробнее

Dr. Pavlick on Importance of Immunotherapy in Metastatic MelanomaПодробнее

Dr. Luke Discusses PD-1 Inhibitors for MelanomaПодробнее

Influence of new immunotherapy checkpoint inhibitors in melanomaПодробнее

Current Trends in Melanoma TreatmentПодробнее